Disease Intelligence Center · Pandemic III
Asthma & Allergic Airway Disease
Airway inflammation is mapped against indoor and outdoor exposures, immune phenotype, microbial ecology and nutrient status, with guideline therapy always in the foreground.
Domain weighting
Organizational emphasisiWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.
Root-cause chain
Each link carries its own evidence grade- Allergen and fine-particulate exposure→Type 2 airway inflammationTA
Allergen challenge and pollution exposure studies consistently show eosinophilic airway inflammation and exacerbation risk.
Relationship: Established causal
- Mast-cell and eosinophil activation→Bronchial hyperresponsivenessIA
Mediator release drives smooth-muscle constriction, edema and mucus production.
Relationship: Established causal
- Indoor mold and water-damage history→Respiratory symptom burdenIB
Dampness indices associate with asthma symptoms; specific causal agents are rarely isolated.
Relationship: Observational association
- Vitamin D insufficiency→Exacerbation frequencyNB
Meta-analyses show reduced exacerbations with repletion in deficient patients.
Relationship: Randomized evidence
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.
Fifth Estate considerations
Microbial ecologyRespiratory virome and airway bacteriome are assessed as exacerbation triggers; colonization is distinguished from active infection before antimicrobials are considered.
Go deeper
TOBIN Intelligence LibraryThe full evidence review for Asthma & Allergic Airway Disease: each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.
Open the Asthma & Allergic Airway Disease evidence reviewProtocol Fusion Engine
Six lanes · evidence grade and regulatory status on every entryConventional
Guideline-preferred therapy reducing exacerbations across severities.
Caution: Review technique; oral candidiasis and dysphonia with poor rinse habits.
Functional
Reduces trigger load in dampness and allergen-heavy homes.
Caution: Remediation must not delay controller therapy.
Integrative
Improves symptom scores and quality of life as an adjunct.
Caution: Adjunct only; does not alter airway inflammation.
Orthomolecular
Reduces exacerbation rate in deficiency.
Caution: Dose to measured level; not a controller substitute.
Traditional
Traditional symptom relief with little controlled evidence.
Caution: Burn risk; essential-oil aerosols can trigger bronchospasm.
Energy / Physical
Energy medicine on Tayapulse →No adequate evidence of benefit.
Caution: Must never replace controller or rescue therapy.
iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.
iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.
Diagnostics to consider
- · Spirometry with reversibility
- · FeNO and blood eosinophils
- · Specific IgE or component testing
- · Home dampness and exposure history
Monitoring
- · Symptom control score at each visit
- · Inhaler technique and adherence
- · Exacerbation and steroid-burst count
Prevention emphasis
- · Allergen and irritant reduction at home
- · Fragrance and aerosol avoidance
- · Air filtration during high-pollution days
- · Vaccination per guideline